Artivila Therapeutics is a pharmaceutical company established in 2018 and based in Shenzhen, China. The company specializes in biotechnology and is dedicated to improving patient outcomes through innovative drug discovery. Utilizing an AI-powered platform, Artivila focuses on developing new therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. Its integrated approach aims to consistently and efficiently deliver first-in-class drug candidates, positioning Artivila at the forefront of pharmaceutical research and development.
Provider of an AI-enabled drug and disease discovery platform. The company provides a drug and disease discovery platform empowered by machine learning and AI to discover novel disease targets, screen for potential drugs, repurpose existing drugs for new indication and optimization ADMET property prediction, enabling a more efficient way to generate new insights and discover more effective medicines to decipher disease biology.
China Xishan Science & Technology Co., Ltd. researches, develops, manufactures, and sells medical devices. The company provides basic equipment for surgical operations in hospitals. Its products are mainly applied to bone tissue dispose in surgery, such as high-speed neurosurgical perforating and burring; fixer embedding and sawing for orthopedics operation; operation for micro bone; operation for protrusion of lumbar vertebral disc; and ENT and plastic surgery. The company was founded in 1992 and is based in Chongqing, China.
Sumgen is an antibody drug developer focused on creating innovative therapeutic antibody drugs for the treatment of tumors and other diseases. The company specializes in immunotherapy and immunodiagnosis, employing advanced technologies such as computer-aided design and mammalian cell display to screen and optimize antibody candidates. By leveraging its unique research and development methodologies, Sumgen aims to produce effective antibody drugs that provide patients with targeted treatment options for major diseases, including cancer.
Longhui Medical is a medical robotics R&D company focused on joint replacement surgery robots, product development, sales, and service.
Sepax Technologie is a biotechnology firm that offers ion exchange, hydrophobic interaction, and method development services.
Shanghai Ouyi Biomedical Technology Co., Ltd., established in 2009, is a high-tech enterprise of multi-omics testing services with "specialization, specialization and new". It has built a multi-omics testing platform covering nucleic acid, protein, and metabolism. Big data analysis platform combined with multi-omics. For pharmaceutical, food and daily chemical companies; life sciences, medicine and clinical research fields, provide drug target discovery, pharmacological efficacy and safety evaluation, disease molecular marker screening, pathogenic bacteria and drug resistance traceability, life development research and Multi-level and multi-omics testing services and solutions for disease occurrence and development research.
Brise Pharma
Angel Round in 2021
Brise Pharma operates in the scientific research and technical service industry.
Developer of gene sequencing technology designed to promote the development of precision medicine. The company's business scope covers software and hardware for sequencers, sample processing, consumables, reagents and data processing, enabling genetic sequencing to be a routine detection and diagnostic tool for medical industry.
Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate and comprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life.
Developer of biological R&D platform intended to discover antibody new drugs. The company develops antibody drugs to better treat cancer and tumor diseases, enabling patients to get better treatments.
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.
Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.
GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative pharmaceuticals and antibody drugs that target various cancer systems. Its efforts are directed at reactivating tumor-specific immune responses and mobilizing the body's own immune system to combat cancer. GenFleet Therapeutics serves both domestic and international markets, contributing to advancements in cancer therapy through its development of signal transduction regulators, tumor microenvironment modulators, and transcription factors.
ArteryFlow is an intelligent diagnostic system developer, which combines computational fluid dynamics, 3D medical image reconstruction, big data and artificial intelligence technology, and provides intelligent diagnosis, image-assisted diagnosis, technical training and guidance to users in scientific research institutions, hospitals, clinics and other fields by using technical means such as automated grid generation, virtual therapy, accurate diagnosis, etc
Baicare aims to improve the level of clinical microbiological testing and promote the rational use of antibiotics. Based on microfluidic chips and gene detection technology, it provides intelligent automated nucleic acid detection products for clinical hospitals. One chip can quickly and accurately detect pathogenic bacteria. And its drug resistance, to provide doctors with effective treatment programs, reduce patient suffering, and significantly save social medical costs. Baicare has developed rapidly and won a number of financial support such as the “13th Five-Year National Science and Technology Major Project” . It has applied for more than 20 related patents and was awarded “National High-Tech Enterprise”. Baikangxin has also been favored by medical experts and the capital market.
The Senyi team is composed of elites from well-known universities and well-known companies at home and abroad. It integrates experts in areas such as artificial intelligence, medicine, medical informatics, and medical informationization. The core team's technical achievements have been applied to a number of national and municipal projects. He has published more than 20 papers in international top journals and has spoken at top international medical conferences.
Private Equity Round in 2019
Novena Global Lifecare is a unique integrated Healthcare platform.
Suzhou And Science Technology Development Corp, established in 2006 and located in Zhangjiagang, China, specializes in the manufacturing of surgical instruments and medical devices. The company focuses on developing products primarily for use in operating rooms, emergency rooms, and treatment rooms. Its product portfolio includes a range of innovative solutions such as the "AND" brand minimally invasive vertebroplasty system, medical vacuum drainage systems, high-pressure pulse irrigation systems, single-use irrigators, external fixation systems, and DC orthopedic drill chainsaws. Through its commitment to advancing medical technology, the company aims to enhance surgical procedures and patient care.
Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.
Kanglu Bio is positioned to provide clinical diagnosis and guidance for clinical drug molecular diagnostic products and clinical molecular diagnostics overall service providers for clinical hospitals and third-party clinical independent testing institutions. The products and services are mainly used in cardiovascular and cerebrovascular diseases. Major diseases such as tumors and cancer.
Skynor Medical
Series A in 2018
Skynor Medical is a minimally invasive vascular intervention equipment supplier.
Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, focuses on developing innovative oncolytic virus therapeutics aimed at treating cancer. Utilizing its proprietary Synerlytic™ technical platform, the company enhances cancer treatment by harnessing immunological principles to create therapies that stimulate and amplify the body's immune response against tumors. Virogin's approach is centered on leveraging multiple payload expressions to generate a robust and transient antiviral immune response, thereby improving systemic antitumor immunity. With its commitment to advancing immunotherapy, Virogin aims to establish itself as a leader in the field of immuno-oncology.
GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative pharmaceuticals and antibody drugs that target various cancer systems. Its efforts are directed at reactivating tumor-specific immune responses and mobilizing the body's own immune system to combat cancer. GenFleet Therapeutics serves both domestic and international markets, contributing to advancements in cancer therapy through its development of signal transduction regulators, tumor microenvironment modulators, and transcription factors.
Dr. Yu Pediatrics Clinics is a healthcare provider based in Chongqing, China, specializing in pediatric services. The clinic focuses on delivering comprehensive medical care to children, addressing a range of health issues from routine check-ups to specialized treatments. By prioritizing child-friendly practices and environments, Dr. Yu Pediatrics Clinics aims to ensure a positive healthcare experience for both children and their families. The clinic's commitment to quality care positions it as a trusted resource for pediatric health in the region.
LinaTech is a healthcare company specializing in the development and manufacturing of precision radiotherapy equipment for tumor treatment. The company creates informatics software designed to enhance the management of cancer clinics, radiotherapy centers, and medical oncology practices. Additionally, LinaTech produces image guidance series products and stereotactic radiotherapy equipment, equipping medical institutions with advanced tools for the calculation, positioning, treatment, and verification of radiotherapy procedures. Through its innovative solutions, LinaTech aims to improve the effectiveness and accuracy of cancer treatment.
Eccogene is a healthcare company focused on developing treatments for metabolism and immune-related diseases, particularly obesity and diabetes. The company specializes in disease biology, medicinal chemistry, and translational science to create immunological pharmaceuticals at the molecular level. Eccogene aims to address complex chronic diseases by providing a pipeline of metabolic drugs designed to enhance patient outcomes and improve overall health.
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.
The company was founded in 2003 and is headquartered in San Diego, California.
Eyebright Medical Technology Co., Ltd., founded in 2010 and based in Beijing, China, specializes in the development and production of ophthalmic medical products. The company offers a diverse range of items, including surgical implants, instruments, optometric lenses, and eye drops, aimed at treating various ophthalmic diseases such as cataracts, glaucoma, and refractive errors. In addition to its product offerings, Eyebright is involved in research and development, sales, and related services within the ophthalmic medical device sector, ensuring a comprehensive approach to addressing vision problems.
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.
Hangzhou Ancare Medical Technology Co., Ltd operates a psychological diagnosis and treatment service platform. The company is headquartered in Hangzhou, China.
Virtual Incision is the pioneer of in vivo mini-robot surgery, enabling minimally-invasive colon resection and other abdominal procedures. Colorectal cancer is the second-deadliest form of the disease, and along with conditions like Diverticulitis and Crohn’s, treatment often requires a colectomy, almost 400,000 of which are performed each year in the U.S. alone. Two-thirds of these procedures are still performed open, requiring a long, gruesome incision. VIC’s simpler/easier/cheaper approach is to insert a mini-robot into the insufflated abdomen via a small umbilical incision, after which the highly-dextrous robot arms are freely manipulated at the nearby surgeon console. VIC enables MIS colectomy using well-known laparoscopic tools, onboard vision, and leading multi-quadrant capabilities. After 70+ pig labs and with 60+ patents/applications, VIC is seeking a $15M Series B financing to achieve First-in-Man and prepare for CE Mark and FDA 510(k) submissions.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.
Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.
Provider of industry solutions intended for medical devices manufactures. The company provide medical equipment businesses with solutions including device design, risk management, marketing, product verification and validation, and product registration, enabling enterprises to develops and launch safe, high quality, and affordable products, and grow business and sustainability.
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company is advancing a pipeline of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Notably, it is developing D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor, and is exploring combinations of its drugs with other immuno-oncology therapies, such as PD-1 antibodies, for various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with prior experience at major pharmaceutical companies like Merck and Schering-Plough, InventisBio aims to leverage their expertise in oncology and metabolic diseases to bring effective treatments to market.
Anbiping focuses on the research and development, production and service of pathological diagnosis products.